公开(公告)号：US10829453B2

公开(公告)日：2020-11-10

申请号：US16179637

申请日：2018-11-02

Applicant: University of Kansas ,  THE SCRIPPS RESEARCH INSTITUTE

Inventor： Jeffrey Aube ,  Kevin Frankowski ,  Thomas Prisinzano ,  Laura Bohn

IPC: C07D217/08 ,  C07D209/44 ,  C07D223/16

Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (KOR) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.

公开(公告)号：US20190300486A1

公开(公告)日：2019-10-03

申请号：US16179637

申请日：2018-11-02

Applicant: University of Kansas ,  THE SCRIPPS RESEARCH INSTITUTE

Inventor： Jeffrey Aube ,  Kevin Frankowski ,  Thomas Prisinzano ,  Laura Bohn

IPC: C07D217/08 ,  C07D209/44 ,  C07D223/16

Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (KOR) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.

公开(公告)号：US10118896B2

公开(公告)日：2018-11-06

申请号：US15529290

申请日：2015-11-25

Applicant: University of Kansas

Inventor： Jeffrey Aube ,  Kevin Frankowski ,  Thomas Prisinzano ,  Laura Bohn

IPC: C07D217/08 ,  C07D209/44 ,  C07D223/16

Abstract: The present technology is directed to compounds, compositions, and methods related to non-morphinan-like kappa opioid receptor (KOR) antagonists. The technology is suited to treat addiction, diuresis, depression, post traumatic stress disorder, an eating disorder, panic disorder, social anxiety disorder, general anxiety disorder, obsessive compulsive disorders, excessive or unreasonable specific phobias, and/or other conditions related to anxiety or aversion-reward responses.